NCT01365338 is a Phase 1 clinical trial of PF-04958242 in Healthy Volunteer, sponsored by Biogen.

Who is sponsoring NCT01365338?

NCT01365338 is sponsored by Biogen.

What drugs are being tested in NCT01365338?

Interventions in NCT01365338: Placebo, PF-04958242.

What condition does NCT01365338 study?

NCT01365338 studies Healthy Volunteer.

Is NCT01365338 still recruiting?

NCT01365338 is currently completed. Last updated 24 December 2019.

Last reviewed 2019-12-24 · How we verify

NCT01365338

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects

Completed Phase 1 Last updated 24 December 2019

What this trial tests

Phase 1 trial testing Placebo in Healthy Volunteer in 112 participants. Completed in 14 December 2012.

Timeline

24 June 2011

Primary endpoint
14 December 2012

14 December 2012

Quick facts

Lead sponsor	Biogen
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	112
Start date	24 June 2011
Primary completion	14 December 2012
Estimated completion	14 December 2012
Sites	2 locations across United States

Drugs / interventions tested

Placebo
PF-04958242 — full drug profile →

Conditions studied

Healthy Volunteer — all drugs for Healthy Volunteer →

Sponsor

Biogen — full company profile →

Who can join

Adults 21 to 55, any sex, with Healthy Volunteer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study aims to determine whether the drug affects brain activity in healthy volunteers, either when the participants are performing a memory task, or when lying at rest. Subjects will undergo a brain scan under both of these conditions after a dose of either the study drug or a placebo is administered.The secondary objective is to evaluate the safety and tolerability of the four doses of PF-04958242 administered orally to healthy adult participants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road.
Kadriu B, Musazzi L, Johnston JN, Kalynchuk LE, et al · · 2021 · cited 37× · PMID 34358693 · DOI 10.1016/j.drudis.2021.07.027

Verify or expand the search:

Other trials of PF-04958242

Trials testing the same drug.

NCT02855411 — A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizop · Phase 2 · terminated
NCT02341482 — A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects · Phase 1 · completed
NCT02332798 — Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia · Phase 1 · completed
NCT02228395 — Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers · Phase 1 · completed
NCT01238679 — Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers · Phase 1 · terminated

Other recruiting trials for Healthy Volunteer

Currently open trials in the same condition.

NCT06274749 — Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Mask · NA · recruiting
NCT05652478 — Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study · Phase 2 · recruiting
NCT06845176 — Combining Motor Imagery and Tendon Vibration on the Effectiveness of Motor Imagery · NA · recruiting
NCT07439263 — Single Ascending Dose Study of HB2198 in Healthy Participants · Phase 1 · recruiting
NCT07220122 — Impact of Exogenous Ketones on Breathing in Healthy Volunteers · EARLY_PHASE1 · recruiting

Other Biogen trials

Trials by the same sponsor.

NCT07483632 — A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses · Phase 3 · not yet recruiting
NCT06628687 — A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it Duri · recruiting
NCT07444450 — A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy · Phase 3 · not yet recruiting
NCT07444489 — A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants · Phase 3 · not yet recruiting
NCT07444476 — A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years Wit · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01365338 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biogen
Last refreshed: 24 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01365338.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing